Retrophin Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Retrophin (RTRX) Misses Q3 EPS by 23c, Revenues Miss
November 1, 2018 4:55 PM EDTRetrophin (NASDAQ: RTRX) reported Q3 EPS of ($0.68), $0.23 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $40.71 million versus the consensus estimate of $44.36 million.
I am pleased with the continued advancement of our first-in-class fosmetpantotenate and sparsentan programs and look... More
